RENXF Stock Chart & Stats
$0.04
>-$0.01(-0.28%)
At close: 4:00 PM EDT
$0.04
>-$0.01(-0.28%)
Day’s Range― - ―
52-Week Range$0.02 - $0.18
Previous CloseN/A
Volume1.00K
Average Volume (3M)35.00
Market Cap
$15.61M
Enterprise Value$22.35
Total Cash (Recent Filing)$6.20M
Total Debt (Recent Filing)$5.80M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume0
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$1.51M
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross MarginSustained revenue growth and a materially higher gross margin indicate the core test is gaining commercial traction and the unit economics are improving. If continued, higher margins support scalable revenue growth, reduce marginal loss per test and improve the pathway to operational break-even over months.
Proprietary Biomarker + AI DiagnosticKidneyIntelX’s combination of biomarkers and AI-driven clinical decision support creates a differentiated diagnostic product. This integration supports durable competitive advantage, sticky clinical relationships and recurring per-test revenue from healthcare systems that adopt the test into care pathways.
Reducing Cash Burn TrendA nearly 40% year-on-year reduction in cash outflow demonstrates improving cost control and operational leverage. Continued reductions in burn, combined with revenue growth, lower near-term financing pressure and improve the company’s ability to extend runway while scaling test volumes.
Bears Say
Negative Equity / Stressed Balance SheetNegative shareholders’ equity signals a stressed capital structure that limits financial flexibility and increases dependence on external financing. This condition can raise counterparty concerns, constrain long-term contracting with health systems and elevate refinancing and dilution risk.
Persistent Heavy Cash BurnMaterial negative free cash flow at scale implies ongoing financing needs. Persistent cash burn strains execution, risks delaying commercialization investments, and increases the likelihood of equity raises or partnerships that could dilute existing holders or impose restrictive terms.
Very Small Revenue Base Vs Large LossesRevenue remains immaterial relative to operating costs, producing extreme negative margins. A small sales base limits economies of scale and makes profitability highly sensitive to reimbursement, test volume growth and fixed-cost absorption, prolonging the timeline to sustainable profits.
Renalytix News
RENXF FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $0.02 and its highest was $0.18 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $15.61M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 94 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in RENXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―